Solid Biosciences to Attend Notable Investor Conferences
Solid Biosciences Inc. (Nasdaq: SLDB), a pioneering life sciences firm focused on cutting-edge genetic therapies, is set to engage in several prominent investor conferences that allow for valuable discussions about their innovative advancements in treating neuromuscular and cardiac diseases. These conferences represent a platform for Solid to connect with stakeholders and share insights on their ongoing projects that aim to greatly impact the lives of individuals battling rare illnesses.
Conference Details and Participation
At the forefront of these engagements, Bo Cumbo, the President and CEO of Solid Biosciences, will feature in multiple fireside chats, providing a direct avenue for investment discussions. The conferences will take place on the following dates:
- 2025 Citi Biopharma Back to School Conference
Scheduled for September 2, 2025, at 1:45 p.m. ET, this event will host a live webcast for attendees to engage efficiently. - Cantor Global Healthcare Conference
On September 4, 2025, at 3:20 p.m. ET, Mr. Cumbo will delve into the company's recent progress and future outlook. - H.C. Wainwright 27th Annual Global Investment Conference
Planned for September 8, 2025, at 9:00 a.m. ET, this talk will focus on Solid's innovative approach to genetic medicine. - 2025 Baird Global Healthcare Conference
Mark your calendars for September 9, 2025, at 3:10 p.m. ET as Mr. Cumbo shares insights about the company's pivotal research initiatives.
Accessing Conference Webcasts
All fired-up discussions will be streamed live on the company’s website, allowing interested parties to follow along and participate remotely. Furthermore, these discussions will be recorded and made available for replay for up to 90 days after the events, ensuring no valuable information is missed.
Engagement with Institutional Investors
Alongside the public presentations, Solid’s management team will be engaging in one-on-one meetings with institutional investors throughout the conferences. This direct interaction aims to cultivate deeper relationships and provide tailored insights into the company’s strategies and advancements. Institutions interested in setting up these meetings are encouraged to coordinate directly via their respective conference representatives.
About Solid Biosciences
Solid Biosciences is on a mission to develop transformative gene therapy solutions targeting rare and challenging conditions such as Duchenne muscular dystrophy and several genetic cardiac diseases. With a strong focus on innovation and patient-centric solutions, the company strives to push the boundaries of genetic medicine. Their efforts include a robust pipeline of candidate therapies and pioneering technologies that aim to change the landscape of treatment options for patients. Established by individuals personally impacted by rare diseases, Solid radiates a commitment to enhance quality of life for those affected by such conditions.
Contacting Solid Biosciences
Investor Relations
For inquiries regarding investor relations, individuals may contact Nicole Anderson, Director of Investor Relations and Corporate Communications, at investors@solidbio.com.
Media Relations
For media-related inquiries, please reach out to Glenn Silver at glenn.silver@finnpartners.com.
Frequently Asked Questions
What is the main focus of Solid Biosciences?
Solid Biosciences specializes in developing precision genetic medicines for a variety of neuromuscular and cardiac diseases.
Who is leading the discussions at the upcoming conferences?
The President and CEO, Bo Cumbo, will be representing Solid Biosciences during the fireside chats.
Where can I watch the conference webcasts?
Webcasts will be available on the company's website, allowing anyone to tune in live or on replay for up to 90 days.
How does Solid Biosciences support patients?
The company is deeply committed to enhancing patient lives through research and the development of groundbreaking therapies targeting rare diseases.
How can institutional investors arrange meetings with Solid’s management?
Institutional investors can coordinate meetings through their representatives at the respective conferences.
